Clinical Trials

BETA3_LVH: A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with structural heart disease (NCT02599480)
HOMAGE: Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) "HOMAGE" Programme " Heart OMics in AGing "(NCT02556450)
SPIRIT-DHF: SPIRonolactone In the Treatment for Diastolic Heart Failure (DZHK)
TIM-HF II: Telemedical Interventional Management in Heart Failure II (TIM-HF II) (NCT01878630)
TORCH: German Centre for Cardiovascular Research Cardiomyopathy Register (TORCH) (DZHK) (NCT02187263)
Transition-CHF: Systolic Dysfunction to Congestive Heart Failure Cohort Study (TransitionCHF) (DZHK)

Ex-DHF: Exercise Training in Diastolic Heart Failure (DFG)

Ex-VAD: Exercise Training in patient with left ventricular assist device (DZHK)
OptimEx: Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure (OptimEx-Clin) (NCT02078947)
Transition-CHF: Systolic Dysfunction to Congestive Heart Failure Cohort Study (TransitionCHF) (DZHK)
FIX-HF-5C: Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects with Moderate-to-Severe Heart Failure with EF between 25% and 45% (FIX-HF-5C) (NCT01381172)

SOCRATES-PRESERVED: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure, ClinicalTrials.gov Identifier: NCT01951638

SOCRATES-REDUCED: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED), ClinicalTrials.gov Identifier: NCT01951625
OptimEx: Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure – TU München
ClinicalTrials.gov Identifier: NCT02078947
Ex-DHF: Exercise Training in Diastolic Heart Failure – University of Göttingen
BaroStim: Barostim Therapy™ in Heart Failure with Preserved Ejection Fraction – CVRX

Serelaxin in experimental heart failure: an in vivo serial MRI and biochemical analysis (ongoing)
Selective decrease of C-reactive protein using CRP-apheresis in patients with acute myocardial infarction.(ongoing)
COMeDY-Study (colchicine for the treatment of inflammatory cardiomyopathy (in preparation)
Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging (published: Kelle S et al. JACC 2009)
A bi-center cardiovascular magnetic resonance prognosis study focusing on dobutamine wall motion and late gadolinium enhancement in 3,138 consecutive patients (published: Kelle S et al. JACC 2013)
Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial (published: Mahfoud F et al. EHJ 2014)
NIH-Trial (Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy.) (Germany: lead by J. Schulz-Menger)
CMR Bayer Trial "GadaCAd" (Germany: lead by J. Schulz-Menger)

Distribution of novel iron particles for tumor therapy (industry-sponsored)
In-vitro localisation of renal stem-cell implants (Charité/Berlin-Brandenburg Center of Regenerative Therapies BCRT)
Myocardial remodeling and fibrosis in acute heart failure (industry-sponsored)
Myocardial injury in Experimental Autoimmune Myocarditis (Charité, German Heart Institute Berlin)

PARSiFAL: A double blinded, placebo controlled, study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 receptor agonist BAY 1067197 in patients with chronic systolic heart failure: the PARSiFAL-pilot study. EudraCT No.: 2013-002522-23

CUPID: A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure. EudraCT No: 2012-001700-37
COSMIC-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction. EudraCT No: 2012-000327-40
CHIARA-MIA: A single blind, multicenter pilot study to investigate the safety and tolerability of a 14 day oral treatment with different doses of the chymase inhibitor BAY 1142524 in comparison to placebo in clinically stable patients with left-ventricular dysfunction after myocardial infarction.
EudraCT No: 2014-005297-12
VENICE: Evaluation of the effect of 0.4 mg nitroglycerin spray after pretreatment with multiple once daily oral doses of 2.5 mg, 5 mg and 10 mg vericiguat (BAY 1021189) each given over 14 ± 3 days on safety, tolerability and blood pressure in a multi-center, randomized, placebo-controlled, double-blind group comparison study in stable coronary artery disease (CAD) patients aged 30 to 80 years. EudraCT No: 2015-001444-11